Thrombotic microangiopathy in children

被引:23
作者
Palma, Lilian Monteiro P. [1 ]
Vaisbich-Guimaraes, Maria Helena [2 ]
Sridharan, Meera [3 ]
Tran, Cheryl L. [4 ]
Sethi, Sanjeev [5 ]
机构
[1] State Univ Campinas UNICAMP, Dept Pediat, Pediat Nephrol, Rua Tessalia Vieira Camargo,126 Cidade Univ, BR-13083887 Campinas, SP, Brazil
[2] State Univ Sao Paulo USP, Pediat Nephrol, Sao Paulo, Brazil
[3] Mayo Clin, Dept Internal Med, Hematol, Rochester, MN USA
[4] Mayo Clin, Dept Pediat, Pediat Nephrol, Rochester, MN USA
[5] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
关键词
Thrombotic microangiopathy; Complement; DGKe; Hypertension; Infection; Hemolytic uremic syndrome; Transplant; HEMOLYTIC-UREMIC SYNDROME; COMPLEMENT INHIBITOR ECULIZUMAB; VON-WILLEBRAND-FACTOR; THROMBOCYTOPENIC PURPURA; PEDIATRIC-PATIENTS; CRITICAL-APPRAISAL; ESCHERICHIA-COLI; ADULT PATIENTS; MUTATIONS; INFECTION;
D O I
10.1007/s00467-021-05370-8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The syndrome of thrombotic microangiopathy (TMA) is a clinical-pathological entity characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end organ involvement. It comprises a spectrum of underlying etiologies that may differ in children and adults. In children, apart from ruling out shigatoxin-associated hemolytic uremic syndrome (HUS) and other infection-associated TMA like Streptococcus pneumoniae-HUS, rare inherited causes including complement-associated HUS, cobalamin defects, and mutations in diacylglycerol kinase epsilon gene must be investigated. TMA should also be considered in the setting of solid organ or hematopoietic stem cell transplantation. In this review, acquired and inherited causes of TMA are described with a focus on particularities of the main causes of TMA in children. A pragmatic approach that may help the clinician tailor evaluation and management is provided. The described approach will allow for early initiation of treatment while waiting for the definitive diagnosis of the underlying TMA.
引用
收藏
页码:1967 / 1980
页数:14
相关论文
共 92 条
[1]   Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy - Proceedings of the American Society of Pediatric Nephrology Educational Symposium, May 2000, Boston, Massachusetts, USA [J].
Andreoli, SP ;
Trachtman, H ;
Acheson, DWK ;
Siegler, RL ;
Obrig, TG .
PEDIATRIC NEPHROLOGY, 2002, 17 (04) :293-298
[2]   Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network [J].
Ardissino, Gianluigi ;
Possenti, Ilaria ;
Vignati, Chiara ;
Daprai, Laura ;
Capone, Valentina ;
Brigotti, Maurizio ;
Luini, Mario Vittorio ;
Consonni, Dario ;
Montini, Giovanni .
PEDIATRIC NEPHROLOGY, 2020, 35 (10) :1997-2001
[3]   Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome [J].
Ardissino, Gianluigi ;
Tel, Francesca ;
Possenti, Ilaria ;
Testa, Sara ;
Consonni, Dario ;
Paglialonga, Fabio ;
Salardi, Stefania ;
Borsa-Ghiringhelli, Nicolo ;
Salice, Patrizia ;
Tedeschi, Silvana ;
Castorina, Pierangela ;
Colombo, Rosaria Maria ;
Arghittu, Milena ;
Daprai, Laura ;
Monzani, Alice ;
Tozzoli, Rosangela ;
Brigotti, Maurizio ;
Torresani, Erminio .
PEDIATRICS, 2016, 137 (01)
[4]   The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment [J].
Ariceta, Gema ;
Dixon, Bradley P. ;
Kim, Seong Heon ;
Kapur, Gaurav ;
Mauch, Teri ;
Ortiz, Stephan ;
Vallee, Marc ;
Denker, Andrew E. ;
Kang, Hee Gyung ;
Greenbaum, Larry A. .
KIDNEY INTERNATIONAL, 2021, 100 (01) :225-237
[5]   Factor H and the pathogenesis of renal diseases [J].
Ault, BH .
PEDIATRIC NEPHROLOGY, 2000, 14 (10-11) :1045-1053
[6]   C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome [J].
Balestracci, Alejandro ;
Meni Bataglia, Luciana ;
Toledo, Ismael ;
Beaudoin, Laura ;
Alvarado, Caupolican .
PEDIATRIC NEPHROLOGY, 2020, 35 (02) :331-339
[7]   IMPROVED SURVIVAL IN THROMBOTIC THROMBOCYTOPENIC PURPURA HEMOLYTIC UREMIC SYNDROME - CLINICAL-EXPERIENCE IN 108 PATIENTS [J].
BELL, WR ;
BRAINE, HG ;
NESS, PM ;
KICKLER, TS .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (06) :398-403
[8]   Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study [J].
Bendapudi, Pavan K. ;
Hurwitz, Shelley ;
Fry, Ashley ;
Marques, Marisa B. ;
Waldo, Stephen W. ;
Li, Ang ;
Sun, Lova ;
Upadhyay, Vivek ;
Hamdan, Ayad ;
Brunner, Andrew M. ;
Gansner, John M. ;
Viswanathan, Srinivas ;
Kaufman, Richard M. ;
Uhl, Lynne ;
Stowell, Christopher P. ;
Dzik, Walter H. ;
Makar, Robert S. .
LANCET HAEMATOLOGY, 2017, 4 (04) :E157-E164
[9]   Various phenotypes of disease associated with mutated DGKE gene [J].
Bezdicka, Martin ;
Pavlicek, Petr ;
Blahova, Kveta ;
Hacek, Jaromir ;
Zieg, Jakub .
EUROPEAN JOURNAL OF MEDICAL GENETICS, 2020, 63 (08)
[10]   Solvent/detergent treatment of human plasma -: A very robust method for virus inactivation.: Validated virus safety of OCTAPLAS® [J].
Blesert, L ;
Suhartono, H .
VOX SANGUINIS, 1998, 74 :207-212